Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder (MDD) in adults. Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran.
- Mechanism
- Curator reviewed · 3 references
Levomilnacipran is a potent and selective selective serotonin and norepinephrine reuptake inhibitor (SNRI). The exact mechanism of the antidepressant action of levomilnacipran is unknown but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system through inhibition of reuptake at serotonin and norepinephrine transporters. Like milnacipran, levomilnacipran is a more potent inhibitor of the norepinephrine transporter than the serotonin transporter: it exhibits over a 15-fold higher selectivity for norepinephrine versus serotonin reuptake inhibition.
- Primary indication
- Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in adults.Curator reviewed · 1 structured indication
- Formula / weight
- C15H22N2O · 246.348 g/mol (avg)
- First approval
- Canada, 2022 · United States, 2013
- Also known as
- (1S,2R)-milnacipran · CYCLOPROPANECARBOXAMIDE, 2-(AMINOMETHYL)-N,N-DIETHYL-1-PHENYL-, (1S,2R)- · MILNACIPRAN, (1S,2R)-
- Code names
- F-2695
- Brand names
Resolves to
GJJFMKBJSRMPLA-DZGCQCFKSA-NSMILESCCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Levomilnacipran, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account